Subcutaneous Ketamine: Clinical Use, Onset, and Bioavailability

What Is Subcutaneous Ketamine Administration?

Subcutaneous ketamine administration means delivering ketamine by injecting it into the fatty tissue just beneath the skin, not into a vein, a muscle, or the nasal cavity. The abbreviation you'll often see in clinical notes and research papers is SC or SQ.

If you're researching subcutaneous ketamine administration clinical use, you may have encountered it in discussions about chronic pain, palliative care, or, more recently, treatment-resistant depression. This page explains what the subcutaneous route actually is, how it compares to other delivery methods in terms of bioavailability and onset, and in which clinical contexts it tends to appear.

This article is educational. It does not recommend or discourage any treatment. Decisions about ketamine, including route, dose, and setting, require evaluation by a licensed clinician who knows your full medical history.

Bioavailability: How Much Ketamine Actually Reaches the Bloodstream?

Bioavailability describes the fraction of an administered drug that enters systemic circulation in an active form. For the subcutaneous route, published pharmacokinetic data generally places ketamine bioavailability at approximately 93%, compared to roughly 20-25% for oral administration and near-100% for intravenous infusion.

The reason SC bioavailability is high relates to anatomy. The subcutaneous layer, the tissue directly beneath the skin, has a robust capillary network. Once injected there, ketamine absorbs gradually into those capillaries and enters the bloodstream without first passing through the gastrointestinal tract and liver. This skips what pharmacologists call the first-pass effect, which is why oral ketamine loses a large portion of its dose before it ever reaches the brain.

Understanding ketamine onset time by route of administration matters because onset affects how clinicians structure a session, what monitoring is in place, and how quickly adverse effects might need to be managed. The SC route sits between IV (fastest onset, most precise titration) and oral (slowest onset, most variable absorption).

It's worth noting that bioavailability figures in published literature can vary depending on the study population, injection site, concentration used, and individual differences in subcutaneous tissue perfusion. No single figure applies universally.

Where Subcutaneous Ketamine Appears in Clinical Practice

Subcutaneous ketamine has the longest documented use in palliative care and chronic pain management. In these contexts, clinicians have used SC infusions, delivered via a small needle and a portable syringe driver, to control refractory pain in patients for whom IV access is difficult, who are being cared for at home, or who are near the end of life. Reviews published in palliative medicine literature describe it as a practical option when the goal is sustained analgesia without repeated venipuncture.

Australia and some European countries have relatively more published clinical experience with SC ketamine for palliative pain than the United States does, partly because of differences in how at-home infusion care is organized and funded. This geographic variation matters when reading the literature: study populations, dosing protocols, and monitoring standards may not translate directly across healthcare systems.

For chronic pain conditions outside palliative care, such as complex regional pain syndrome or neuropathic pain, SC ketamine has appeared in case series and small trials, typically at sub-anesthetic doses delivered over hours or days. Evidence quality in this area remains limited, with few large randomized controlled trials.

Psychiatric Applications: Research Context

Interest in subcutaneous ketamine for psychiatric conditions, particularly depression and treatment-resistant depression, has grown alongside broader ketamine research. A number of small trials and retrospective studies have examined SC protocols for this use, often comparing them to IV infusion in terms of clinical response, tolerability, and practical feasibility.

A 2021 study published in the Journal of Psychopharmacology examined SC ketamine for treatment-resistant depression and reported that a portion of participants showed meaningful symptom improvement, with a tolerability profile broadly similar to IV in that controlled setting. However, that study was small, and the authors noted the need for larger trials. Readers should weigh these findings with the caution appropriate to early-phase research.

Researchers conducting these psychiatric trials generally administer SC ketamine in supervised clinical settings, not in home or unsupervised environments, with monitoring for dissociation, cardiovascular changes (ketamine can transiently raise blood pressure and heart rate), and psychological distress. The monitoring requirements for SC administration are substantively similar to IV, because the drug reaches systemic circulation at similarly high levels.

Learn more about how measurement-based care approaches are being studied in the context of treatment-resistant depression and ketamine research.

Practical Considerations: Injection Site, Concentration, and Volume

Subcutaneous injections are typically placed in sites with adequate fatty tissue, the abdomen, upper arms, and thighs are common. For ketamine infusions, a small-gauge needle or a dedicated subcutaneous infusion set (sometimes called a butterfly needle) is inserted and taped in place so the drug can be delivered slowly over time via a pump.

Clinicians must be attentive to the concentration and volume of the solution being infused. Subcutaneous tissue tolerates fluid delivery more slowly than intravenous tissue, and highly concentrated or poorly-buffered solutions can cause local discomfort, erythema (redness), or tissue irritation at the injection site. Published clinical protocols for SC ketamine in palliative care address these parameters in detail, and they vary across institutions.

The injection site itself can influence absorption rate. Tissue perfusion differs between sites and across individuals depending on body composition, temperature, and circulation. This variability is one reason why SC ketamine dosing and monitoring must be individualized by a clinician rather than applied from a general reference.

Regulatory and Prescribing Context in the United States

In the United States, ketamine is classified as a Schedule III controlled substance under the Controlled Substances Act, meaning it has recognized medical uses but also a potential for misuse. The DEA regulates who may prescribe and dispense it.

The FDA has not approved any specific ketamine product for the subcutaneous route. When clinicians use SC ketamine, whether for pain or psychiatric conditions, they are using racemic ketamine (the form that has been on the market since the 1970s as an anesthetic) in an off-label manner. Off-label use is legal and common in medicine, but it places additional responsibility on the prescribing clinician to document clinical rationale and obtain informed consent.

Esketamine nasal spray (Spravato) is FDA-approved for treatment-resistant depression and major depressive disorder with acute suicidal ideation, and it carries a Risk Evaluation and Mitigation Strategy (REMS) program requiring in-office administration and monitoring. The SC route does not have a parallel FDA approval or REMS program, which affects how clinicians must document and justify its use. For more on the regulatory landscape, see our overview of DEA telehealth prescribing developments.

Adverse Effects and Safety Monitoring

The adverse effect profile of SC ketamine overlaps substantially with that of IV ketamine, because both routes deliver ketamine systemically at high bioavailability. Common effects during or shortly after administration include dissociation (a sense of detachment from one's body or surroundings), perceptual changes, dizziness, nausea, and transient increases in blood pressure and heart rate.

Local adverse effects specific to the SC route include injection-site pain, redness, swelling, and, with repeated use at the same site, tissue irritation or subcutaneous nodule formation. Rotating injection sites and using appropriate drug concentrations are standard clinical strategies for reducing these risks.

Longer-term safety considerations for ketamine generally, including effects on the urinary tract (ketamine-induced uropathy has been documented with heavy recreational use) and potential for psychological dependence, apply to SC use as with other routes, though published data specifically on SC ketamine populations is more limited than for IV. Readers researching this area may want to review our guide on ketamine and esketamine side effects and discontinuation rates.

Clinicians using SC ketamine are expected to screen patients for contraindications, including uncontrolled hypertension, certain cardiovascular conditions, a personal or family history of psychosis, and active substance use disorders, before initiating treatment.

How SC Ketamine Fits Into the Broader Treatment Routes Picture

Subcutaneous ketamine is one option within a range of ketamine delivery methods, each with distinct tradeoffs involving bioavailability, onset speed, setting requirements, monitoring intensity, and regulatory status. No single route is universally superior; clinicians weigh individual patient factors, available infrastructure, and the evidence base for the target indication.

For readers trying to understand how routes differ across these dimensions, our ketamine treatment methods guide provides a broader comparison. Understanding those differences helps you engage more meaningfully with your clinical team about why a particular route has been recommended, or not recommended, in your situation.

The subcutaneous route merits attention in part because it opens practical pathways not available with IV, particularly for patients without reliable venous access or in settings (such as palliative home care in some countries) where portable infusion devices can be managed outside a hospital. Whether those practical advantages are relevant to your situation is a conversation for your clinician.